Peanut Allergen Powder-dnfp: A Novel Oral Immunotherapy to Mitigate Peanut Allergy.
Conclusions: In patients 4 to 17 years old, PAP mitigated ARs, including anaphylaxis, that may occur with accidental peanut exposure. Although there are risks, it was efficacious in more than two-thirds of participants in phase 2 and phase 3 efficacy trials.
PMID: 32718178 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Dougherty JA, Wagner JD, Stanton MC Tags: Ann Pharmacother Source Type: research
More News: Allergy | Allergy & Immunology | Anaphylactic Shock | Children | Clinical Trials | Drugs & Pharmacology | Food Allergy | Gastroenterology | Health Management | Immunotherapy | Peanuts | Respiratory Medicine | Statistics | Study